Efficacy and safety of apatinib mesylate combined with chemotherapy in treatment of advanced gastric cancer
CHEN Guo-yong
XIA Dong
Abstract：Objective:To explore the efficacy and safety of apatinib mesylate combined with OXA+5-Fu/CF in the treatment of advanced gastric cancer.Methods:A total of 130 cases of advanced gastric cancer were included and randomized into two groups.Of the 130 cases,9 fell off and the other 121 completed the whole-course treatment.The patients in the single chemotherapy group(60 in number)were treated with OXA+5-Fu/CF chemotherapy,and those in the combined drug group(61 in number)with Apatinib mesylate combined with OXA+5-Fu/CF chemotherapy,and indicators were compared between the 2 groups.Results:The total effective rate was signifcantly higher in the combined treatment group(68.85%)than in the chemotherapy group(50.00%)(P<0.05).The occurring rate of adverse reactions was of no statistical difference between the 2 groups(P>0.05).The progression-free survival time and survival time in the combined treatment group were(2.44±0.34)years and(3.99±0.56)years,respectively,which were longer than those of(2.00±0.27)years and(2.89±0.50)years in the chemotherapy group(P<0.05).The levels of neuron-specific enolase(NSE),serum carbohydrateantigen 19-9(CA19-9),carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)were significantly lower in the combined treatment group((25.39±3.31)u·mL-1,(6.40±1.85)ng·mL-1,(30.26±3.19)u·mL-1,(22.10±4.83)g·L-1)than in the single chemotherapy group((34.23±4.91)u·mL-1,(10.64±1.63)ng·mL-1,(38.64±4.12)u·mL-1,(30.26±4.82)g·L-1)(P<0.05).Conclusion:OXA+5-Fu/CF chemotherapy and apatinib mesylate are effective and safe in the treatment of advanced gastric cancer.
Keywords：Advanced gastric cancerApatinib mesylateOXA+5-Fu/CF chemotherapy regimenCurative effectAdverse reaction
Publication Date：2023-10-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 360-363 )